We are a biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases.
Our most advanced drug candidate is EB05 (Paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immunity responses. EB05 (Paridiprubart) inhibits Toll-like receptor 4 (TLR4), a key immune signaling protein and an important mediator of inflammation. We are currently evaluating EB05 as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life threatening form of respiratory failure. Based in part on the Phase 2 results of our Phase 2/3 study, the U.S. FDA granted us Fast Track designation. To receive this designation, drug candidates must both treat a serious disease and have non-clinical or clinical data that demonstrate the potential to address an unmet medical need.
We are also developing product candidates for a number of chronic dermatological and inflammatory conditions. We recently reported topline results of a Phase 2b study of our EB01 drug candidate in moderate-to-severe chronic Allergic Contact Dermatitis (ACD), a common, often work-related skin condition. We have an approved clinical trial application for our EB06 monoclonal antibody candidate to conduct a future Phase 2 study in vitiligo. We are also preparing an IND for our EB07 product candidate (paridiprubart) to conduct a future Phase 2 study in systemic sclerosis (SSc).
Edesa Biotech, Inc.
Attn: Investor Relations
100 Spy Court
Markham, ON L3R 5H Canada
Fasken Martineau DuMoulin LLP
Computershare Investor Services Inc.
100 University Avenue, 8th Floor
Toronto, Ontario M5J 2Y1
Tel: (800) 564-6253